搜索到 1000 条关于 d88최신실시간증권DB추출% 텔레popkonDB◀◎ 的文章

如何写一篇高质量的医学文献综述

2011.12.06 如何写一篇高质量的医学文献综述

 理论与应用研究学术论文B 实用性成果报告,理论学习和社会实  践总结C 业务指导与技术管理性文章D 一般动态性信息E 文件、资料参考文献类型:专著[M]、期刊[J]、论文集[C]、报纸[N]、学位论文[D]、报告[R]、标准[S]、专利[P]、联机

2012.01.28 肝功能衰竭的诊治经验和教训

,DB 51umol/L,ALT 1264 u/L,AST 1024u/L,GGT 316 u/L,ALP 197 u/L;HAV、HBV、HCV、HDV、HEV...,腹胀、呕吐、精神萎靡,复查肝功能:TB 374umol/L,DB 187umol/L,ALT909 u/L,AST555 u/L,GGT 243u/L,ALP

2012.09.19 国际泌尿外科学会(SIU)第三十届大会

Congress Venue
Shanghai International Convention Center
No. 2727 Riverside Avenue, Pudong
Shanghai, China
200120 The 30th Congress of the Societe Internationale d'Urologie will be held at the Shanghai International Convention Center (SICC) from Sunday, November 1 to Thursday, November 5, 2009. The SICC is located in the Lujiazui Finance and Trade Center Zone, has hosted many major international conferences, and is renowned for the abundance of options and high-tech resources it offers guests. Visa Letter of InvitationOfficial Visa Letter of invitation can be sent to you by the Chinese Medical Association, upon request. Pre-registration for the 30th SIU Congress is required in order to receive such a letter. If you are planning to visit China with your family, the letter can be issued for up to five family members. These letters do not commit the Congress to any financial obligations, nor do they obligate the Congress to intercede in any way on the participant抯 behalf. The SIU is not able to contact embassies or consulates on behalf of any individual wishing to enter China to attend the SIU 30th Congress in Shanghai. VisaVisas are required for almost all visitors to mainland China. Foreign delegates should apply for visas from their nearest Chinese embassy or consulate as soon as possible to ensure that they receive their visa in due time. Certain conditions apply to visitors whose country of residence is not the same as their country of citizenship. TransportationFor transfers to your hotel, please contact SIUIndividualBooking@pacificworldcn.com The rates are as follows:
From Pudong International Airport to your hotel
Private transfer by car for 1-2 person(s) = US $118
Private transfer by van for 3-4 persons = US $152
From Hong Qiao Airport to your hotel
Private transfer by car for 1-2 person(s) = US $88
Private transfer by van for 3-4 persons = US $106 Delegates from ItalyPlease contact the agency listed below to assist you in making travel arrangements for the 30th Congress of the SIU.
拜耳与 RTW 投资公司携手领投中国生物制药企业箕星药业 D 轮融资

2024.01.08 拜耳与 RTW 投资公司携手领投中国生物制药企业箕星药业 D 轮融资

疗法和解决方案。」拜耳影响力投资部门「飞跃计划」(Leaps by Bayer)携手 RTW 共同领投箕星药业(2019 年由 RTW 孵化)的 D 轮融资。

2009.10.17 李进:Novel Vascular Endothelial Growth Factor Receptor Inhibitor YN968D1 (Apatinib) Against advanced Malignancies: Phase I/II Study

。Novel Vascular Endothelial Growth Factor Receptor Inhibitor YN968D1 (Apatinib... Vascular Endothelial Growth Factor Receptor Inhibitor YN968D1 (Apatinib) Against
骨矿物质密度减少或增加心衰风险

2014.08.21 骨矿物质密度减少或增加心衰风险

调查)研究中年龄位于42-82岁的13666名既往无心脏病发作、卒中或癌症以及无心衰药物治疗的看似健康人群。采用定量超声测量跟骨超声振幅衰减值(BUA,dB /MHz)测定骨矿物质密度,并将BUA按四分位法分为四个区间,分别为≤66.6、66.7-79.3、79.4-92.7和≥92.8 dB /MHz研究平均随访9.3
签约形式

2015.07.23 签约形式

签约形式分两种:一、直接签约就是当面签约,学生或者委托人亲自来中智医学留学申请中心,地址:上海市漕溪北路 88 号圣爱大厦 11 楼,当场交付定金,当场完成签约。二、间接签约就是学生本人不亲自来,而是通过快递完成签约,需要学生在签协议的同时,向中智留学的公告账户上汇入定金。合同签好后,一份保留,另一份快递至中智留学。
2018 BFC 医疗健康国际商务合作投资研讨会

2018.05.25 2018 BFC 医疗健康国际商务合作投资研讨会

会议简介:第四届 BFC 医疗健康产业商务发展与投资合作交流会 2018 将于 6 月 13-15 日在上海威斯汀大酒店(河南中路 88 号)举行。BFC Healthcare 交流会由专注于医疗健康领域跨境商务合作、跨境投资及并购的精品投资银行 BFC Group 主办。会议旨在为医疗健康产业领域搭建一个企业间寻找
品牌

2015.08.26 品牌

R&D Systems、Tocris和Novus Biologicals的母公司于2014年8月正式更名为Bio-Techne。R&D SystemsR&D Systems是细胞生物学试剂的领先供应商,为学术界服务已达40年。R&D Systems供应的产品中97%以上的

2015.08.25 生物活性分析实验指南

BioassayChemotaxis BioassayIntroductionR&D Systems uses... line. TF-1 cells are employed in proliferation bioassays by R&D Systems
助力科研抗疫 | CNGBdb 发布病毒数据库子库:SARS-CoV-2 数据库 v1.0 版

2020.03.03 助力科研抗疫 | CNGBdb 发布病毒数据库子库:SARS-CoV-2 数据库 v1.0 版

筛选需要的目标病毒株,勾选目标病毒株下载元信息表格/序列进行后续研究。操作指引:CNGBdb 首页 → 科学数据库 → Virus DB: 病毒数据库 → SARS-CoV-2 DB:新冠病毒数据库 → 点击表格设置选择元信息 → 点击下载序列/表格。Tips:•一键下载所有序

2013.10.08 Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants

肺癌是严重威胁人类健康的重大疾病,一直占据癌症死亡病例的首位。非小细胞肺癌(NSCLC)则占所有癌症肺癌的85%以上。表皮生长因子受体(EGFR)抑制剂药物易瑞沙(Gefinitib)和特罗凯(Erlotinib)等已在临床治疗非小细胞肺癌病人中获得巨大成功。但其耐药问题也日益突出。耐药的主要原因是EGFR T790M突变,约占耐药病人总数的50%。目前虽有第二代EGFR 非可逆抑制剂(Canertinib、Afatinib、Neratinib、Pelitinib等)进入临床研究,但这些分子缺乏对EGFRT790M突变体的选择性,造成药物临床耐受剂量较低。在其最大耐受剂量( MTD)下,药物无法在体内达到其有效浓度而使得对多数耐药病人无效。多数临床实验也已被迫终止。开发具有高特异性EGFR T790M突变体抑制剂已成为解决Gefitinib等药物临床耐药的一个重要策略,但进展缓慢。该文章中成功设计和合成了Pyrimido[4,5-d]pyrimidin-4(1H)-one类化合物作为全新的特异性EGFR T790M抑制剂。代表性化合物3g对EGFRT790M/L858R 的Kd为2.6 nM,其选择性高达120-240倍。进一步研究表明,化合物在较高浓度下对其它456激酶不产生明显抑制,是目前特异性最高的EGFR T790M突变体抑制剂之一。同时3g也可有效地抑制携带EGFRL858R/T790M 突变的耐药性H1975肺癌细胞的增殖(IC50为86nM),而对携带EGFRWT的正常细胞不产生明显的抑制作用(IC50> 10M)。\r\n
上一页 1 2 3 ... 48 49 50 到第